Results 31 to 40 of about 302,208 (172)

Oncolytic Viruses for Malignant Glioma: On the Verge of Success?

open access: yesViruses, 2021
Glioblastoma is one of the most difficult tumor types to treat with conventional therapy options like tumor debulking and chemo- and radiotherapy.
Yogesh R. Suryawanshi, Autumn J. Schulze
doaj   +1 more source

Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy

open access: yesFrontiers in Pharmacology, 2022
The worldwide burden of cancers is increasing at a very high rate, including the aggressive and resistant forms of cancers. Certain levels of breakthrough have been achieved with the conventional treatment methods being used to treat different forms of ...
Richard Kolade Omole   +14 more
doaj   +1 more source

The current status of oncolytic viral therapy for head and neck cancer

open access: yesWorld Journal of Otorhinolaryngology-Head and Neck Surgery, 2016
Objective: Cancer affects the head and neck region frequently and leads to significant morbidity and mortality. Oncolytic viral therapy has the potential to make a big impact in cancers that affect the head and neck. We intend to review the current state
Matthew O. Old   +4 more
doaj   +1 more source

Oncolytic Virotherapy: From Bench to Bedside

open access: yesFrontiers in Cell and Developmental Biology, 2021
Oncolytic viruses are naturally occurring or genetically engineered viruses that can replicate preferentially in tumor cells and inhibit tumor growth. These viruses have been considered an effective anticancer strategy in recent years.
Ludi Yang   +9 more
doaj   +1 more source

Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients

open access: yesJournal of Translational Medicine, 2012
Oncolytic viruses refer to those that are able to eliminate malignancies by direct targeting and lysis of cancer cells, leaving non-cancerous tissues unharmed.
Patil Sandeep S   +4 more
doaj   +1 more source

Smart Nanotechnologies for Multimodal Neuromodulation and Brain Interfacing

open access: yesAdvanced Science, EarlyView.
Recent advances in smart nanotechnologies are expanding the toolbox for brain interfacing, from wireless neuromodulation and high‐resolution sensing to targeted delivery within the central nervous system. By combining responsive nanomaterials with bioinspired design, these platforms enable multimodal interactions with neurons and glia, while also ...
Tommaso Curiale   +6 more
wiley   +1 more source

Oncolytic adenovirus dl922-947 targets the DNA damage signaling pathway and enhances the effects of radiation therapy [PDF]

open access: yes, 2011
Replication selective oncolytic viruses (OVs) are a rapidly expanding therapeutic platform for cancer treatment. OVs are characterized by genetic alterations that ablate critical viral protein functions essential for viral replication in normal cells ...
Abagnale, Antonella
core   +1 more source

Advances in preclinical and clinical studies of oncolytic virus combination therapy

open access: yesFrontiers in Oncology
Oncolytic viruses represent a distinct class of viruses that selectively infect and destroy tumor cells while sparing normal cells. Despite their potential, oncolytic viruses encounter several challenges as standalone therapies.
Wenlong Du   +4 more
doaj   +1 more source

Natural‐Inspired Engineered Microalgae With Selenium Enrichment Enabled Potent Anti‐Tumor Immunity

open access: yesAdvanced Science, EarlyView.
Se‐Ssp was engineered as a potent immunomodulator for activating innate immunity via the TLR and cGAS‐STING pathways, therefore converting “cold” tumors into “hot” tumors to achieve high efficacy and long‐term therapeutic outcomes. ABSTRACT Immunotherapy has shed light on clinical oncology for several decades.
Yuqi Yang   +11 more
wiley   +1 more source

Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-Region [PDF]

open access: yes, 2012
Oncolytic adenoviruses have shown promising efficacy in clinical trials targeting prostate cancers that frequently develop resistance to all current therapies.
Halldén Gunnel   +36 more
core   +1 more source

Home - About - Disclaimer - Privacy